Physician profile
Benjamin D Supnet
NPI 1508862723
$18,282.51
in general payments reported to CMS, 2019-2025
21 companies · $3,441 in 2025
The $3,441 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,636 · 2020: $1,484 · 2021: $5,357 · 2022: $4,556 · 2023: $1,626 · 2024: $183 · 2025: $3,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,452 · Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,452.37 |
| Food and Beverage | $797.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $10,243.20 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $6,755.66 | 2019-2021 | |
| Abbvie INC. | $306.44 | 2020-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $254.84 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $142.91 | 2024-2025 | Zurzuvae |
| Biogen, INC. | $97.46 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $82.87 | 2022 | |
| Allergan, INC. | $69.06 | 2019 | |
| Myovant Sciences INC. | $44.16 | 2021-2022 | |
| Integra Lifesciences Corporation | $42.14 | 2023-2024 | Integra, Surgimend, Omnigraft |
| Astellas Pharma US INC | $39.30 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $34.65 | 2019-2025 | Slynd |
| Baxter Healthcare | $33.63 | 2021 | |
| Coopersurgical, INC. | $32.76 | 2021-2025 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $24.28 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $21.69 | 2022 | |
| Duchesnay USA Incorporated | $19.34 | 2019 | |
| Evofem Biosciences, INC. | $16.45 | 2022 | |
| Mission Pharmacal Company | $12.47 | 2020 | |
| Aspira Women'S Health INC | $9.20 | 2024 | Ova1 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Supnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.